跳至主要内容
临床试验/JPRN-UMIN000005044
JPRN-UMIN000005044招募中3 期

A randomized competitive trial of Angiotensin II Receptor Blocker (ARB) for prevention of tumor recurrence in non-muscle invasive bladder cancer - ARB therapy for non-muscle invasive bladder cancer

Keio University Hospital0 个研究点目标入组 200 人开始时间: 2011年4月1日最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1.Prior therapy of ARB and/or ACE inhibitor. 2.Normal blood pressure 3.Patients with primary CIS. 4.Presence of active other cancers. Having a severe complications occurred before this study; serious heart failure, renal failure, liver dysfunction, severe infection, and blood trouble. 5.Contraindications for ARB or Calcium channel blocker. (According to attached files of ARB or Calcium channel blocker.) 6.A pregnant women, a woman of breast-feeding, a woman who want to get pregnant. Presence of severe allergy for medicines.

研究者

相似试验